162 related articles for article (PubMed ID: 36928864)
1. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins.
Lenci I; Tariciotti L; Angelico R; Milana M; Signorello A; Manzia TM; Toti L; Tisone G; Angelico M; Baiocchi L
Clin Transplant; 2023 Jun; 37(6):e14971. PubMed ID: 36928864
[TBL] [Abstract][Full Text] [Related]
2. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
[TBL] [Abstract][Full Text] [Related]
3. Transplantation of hepatitis D virus patients: Lifelong hepatitis B immunoglobulins?
Ferenci P; Reiberger T; Stadlbauer V; Zoller H
Liver Int; 2023 Aug; 43 Suppl 1():96-100. PubMed ID: 35767373
[TBL] [Abstract][Full Text] [Related]
4. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
[TBL] [Abstract][Full Text] [Related]
5. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
[TBL] [Abstract][Full Text] [Related]
6. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
[TBL] [Abstract][Full Text] [Related]
7. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis.
Rodríguez-Tajes S; García-Eliz M; Marcos AC; Campos-Varela I; Ros AC; Loinaz C; Gómez Bravo MÁ; Rodríguez-Perálvarez M; Fabrega E; González Diéguez ML; Vinaixa C; Pascasio JM; Vázquez IF; Baliellas C; Castells L; Salcedo M; Prieto M; Crespo G; Lens S; Forns X
Liver Int; 2024 Feb; 44(2):279-285. PubMed ID: 38100141
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
[TBL] [Abstract][Full Text] [Related]
10. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
[TBL] [Abstract][Full Text] [Related]
11. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients.
Manini MA; Bruce M; Whitehouse G; Mazzarelli C; Considine A; Agarwal K; Suddle A; Fagiuoli S; Heaton N; Heneghan M
Transplant Proc; 2021; 53(1):207-214. PubMed ID: 32605776
[TBL] [Abstract][Full Text] [Related]
12. The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation.
Battistella S; Zanetto A; Gambato M; Germani G; Senzolo M; Burra P; Russo FP
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243124
[TBL] [Abstract][Full Text] [Related]
13. Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts.
Orfanidou A; Papatheodoridis GV; Cholongitas E
Liver Int; 2021 Jul; 41(7):1448-1461. PubMed ID: 33656809
[TBL] [Abstract][Full Text] [Related]
14. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation.
Duvoux C; Belli LS; Fung J; Angelico M; Buti M; Coilly A; Cortesi P; Durand F; Féray C; Fondevila C; Lebray P; Martini S; Nevens F; Polak WG; Rizzetto M; Volpes R; Zoulim F; Samuel D; Berenguer M
Aliment Pharmacol Ther; 2021 Sep; 54(5):583-605. PubMed ID: 34287994
[TBL] [Abstract][Full Text] [Related]
15. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
16. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
Stärkel P; Stoffel M; Lerut J; Horsmans Y
Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Newer Nucleos(t)ide Analogs After Hepatitis B Immunoglobulin Discontinuation Against Hepatitis B and D Recurrence in Liver Transplant Recipients.
Cholongitas E; Oikonomou T; Bafa K; Sinakos E; Papatheodoridis GV; Goulis I
Transplantation; 2024 Apr; ():. PubMed ID: 38557857
[TBL] [Abstract][Full Text] [Related]
20. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients.
Radhakrishnan K; Chi A; Quan DJ; Roberts JP; Terrault NA
Transplantation; 2017 Sep; 101(9):2079-2082. PubMed ID: 28880197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
